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Background: Cervical vagus nerve stimulation (VNS) is an emerging bioelectronic treatment for brain,
metabolic, cardiovascular and immune disorders. Its desired and off-target effects are mediated by
different nerve ﬁber populations and knowledge of their engagement could guide calibration and
monitoring of VNS therapies.
Objective: Stimulus-evoked compound action potentials (eCAPs) directly provide ﬁber engagement information but are currently not feasible in humans. A method to estimate ﬁber engagement through
common, noninvasive physiological readouts could be used in place of eCAP measurements.
Methods: In anesthetized rats, we recorded eCAPs while registering acute physiological response
markers to VNS: cervical electromyography (EMG), changes in heart rate (DHR) and breathing interval
(DBI). Quantitative models were established to capture the relationship between A-, B- and C-ﬁber type
activation and those markers, and to quantitatively estimate ﬁber activation from physiological markers
and stimulation parameters.
Results: In bivariate analyses, we found that EMG correlates with A-ﬁber, DHR with B-ﬁber and DBI with
C-ﬁber activation, in agreement with known physiological functions of the vagus. We compiled multivariate models for quantitative estimation of ﬁber engagement from these markers and stimulation
parameters. Finally, we compiled frequency gain models that allow estimation of ﬁber engagement at a
wide range of VNS frequencies. Our models, after calibration in humans, could provide noninvasive
estimation of ﬁber engagement in current and future therapeutic applications of VNS.
© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
The vagus nerve innervates most thoracic and abdominal organs
and relays afferent and efferent information between peripheral
receptors and effector cells and the brain [74]. Cervical vagus nerve
stimulation (cVNS) is emerging as a potential treatment for a
multitude of disorders affecting the brain and peripheral organs,
including drug-resistant epilepsy [2], depression [3], Alzheimer’s
disease [4], anxiety [5], pain [6], tinnitus [7], rheumatoid arthritis
[8], heart failure [9], diabetes [10] and obesity [11], pulmonary
hypertension [12,13], and others. The therapeutic actions of cVNS,

although still under investigation, are mediated by activation of
different types of ﬁbers. For example, anti-epileptic action is
thought to be related to afferent, large, myelinated A-ﬁbers [14],
cardio-inhibitory action in heart failure to efferent, myelinated Bﬁbers [15], and anti-inﬂammatory action by B- and possibly by
afferent, unmyelinated C-ﬁbers [16,17]. In addition, some of the offtarget effects of cervical VNS that often limit its therapeutic efﬁcacy
arise from the activation of large ﬁbers innervating the mucosa and
muscles of the larynx and pharynx [18].
To develop safe and effective VNS protocols for existing and
future indications, optimization of stimulation parameters with
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respect to ﬁber engagement on a single subject basis is essential,
both at the time of electrode implantation and during follow up
visits with health care providers. Fiber-selective VNS has been
demonstrated in experimental animals, but certain stimulation
parameters are different for different subjects [19]. Therefore,
knowledge of ﬁber engagement by a set of stimulation parameters
is crucial in the process of VNS parameter optimization. The main
experimental tool for quantifying ﬁber engagement in peripheral
nerve is registering of stimulus-evoked compound action potentials
(eCAPs) through a recording electrode placed at a known distance
from the stimulating electrode [20]. The conduction velocities of
the different ﬁber types give rise to characteristic patterns of
evoked nerve activity when the nerve is stimulated. These responses are comprised of earlier components, corresponding to
activation of different types of faster A-ﬁbers, intermediate components representing B-ﬁbers, and later components for slower Cﬁbers [21]. Indeed, eCAPs have been used experimentally to optimize stimulation parameters and electrode design in VNS [15,22].
Despite their value, obtaining eCAPs in experimental animals
comes with challenges and is generally limited to acute experiments [23]. In clinical applications, registering eCAPs from the
vagus nerve is not currently feasible. In principle, a quantiﬁable
physiological response mediated by speciﬁc ﬁbers, readily obtainable in experimental animals and in humans, could be used to estimate the magnitude of engagement of those ﬁbers by VNS. For
example, B-ﬁber activity in vagal eCAPs is known to be related to
VNS-related changes in heart rate [24]. However, for a set of
physiological responses to be useful as markers for vagal ﬁber
activation, data-driven models relating those two modalities need
to be compiled and validated. Such models do not exist for VNS.
In our study, we investigated in a rat model the quantitative
relationship between activation of different vagal ﬁber types and
several physiological responses to cervical VNS. We chose physiological responses that can be easily and non-invasively obtained in
experimental animals and in humans, and that are involved in
mechanisms relating to speciﬁc vagal ﬁber types. We characterized
the bivariate associations of stimulus-evoked EMG, heart rate
changes and breathing changes with A-, B- and C-ﬁber eCAP
components respectively, on a single subject basis and across many
subjects. Based on these associations, we built and tested predictive
multivariate models that use physiological responses to VNS to
estimate the magnitude of activation of different ﬁber types. These
models provide the ﬁrst quantitative tool for rapid, non-invasive
estimation of stimulus-evoked vagal ﬁber activation that, after
further evaluation in animal and human studies, could be used to
optimize VNS therapies targeting different organs and diseases on a
single subject basis.

nostrils along with a bridge ampliﬁer (FE221, ADI); the probe reported changes in air temperature during breathing movements:
drop in temperature during inhalation, and rise during exhalation
(Fig. 1A and B). All physiological signals were ﬁrst digitized and
then acquired at 1 kHz (PowerLab 16/35, ADI) and visualized on
LabChart v8 (all from ADInstruments Inc).
Surgical preparation and vagus electrode placement
To expose the cervical vagus nerve (cVN), a midline 3 cm skin
incision was given on the neck (Fig. 1A). Salivary glands were
separated, and muscles were retracted to reach the carotid bundle.
Under a dissecting microscope, the left or right cVN was isolated
ﬁrst at the caudal end of nerve and then at rostral end of nerve. The
middle portion, between the two isolated sites was left intact
within carotid bundle to minimize the extent of surgical manipulation and trauma to the nerve. After isolation of the nerve, a
custom-made, bipolar or tripolar “Flex” electrode was placed on the
caudal site; a second bipolar “Flex” electrode was placed on the
rostral site of cVN. Flex electrodes were made use a polyimide
substrate and sputter-deposited iridium oxide contacts for low
electrode impedances and stable stimulation characteristics
[25e27]. Electrode contacts had dimensions of 1418  167 mm2
with an edge-to-edge spacing of 728 mm and center-to-center
spacing of 895 mm. Typical individual electrode impedances in saline ranged from 0.5 to 1.5 kU. The distance between the stimulating electrode (tripolar: center contact; bipolar distal side
contact) to the most proximal recording electrode on the nerve was
measured roughly 5e6 mm. Silicone elastomer (Kwiksil by World
Precision Instruments) was placed around the cuff to minimize
current leakage during stimulation.
Vagus nerve recording and stimulation
Neural activity from each contact on the recording electrode was
ampliﬁed, digitized (30 kS/s, 16bit resolution) and ﬁltered (60-Hz
notch), using a 32-channel RHS2000 stim/record headstage and
128ch Stimulation/Recording controller (Intan Technologies); recordings were single-ended, relative to a ground lead placed in the
salivary gland. Nerve stimulation was delivered in constant current
mode as trains of monophasic rectangular pulses using an STG4008
stimulus generator (Multichannel Systems). In all experiments
characterizing neural and physiological relationship, we initially
determined the “neural threshold” (NT) as the lowest stimulus
intensity for a 100-ms duration pulses that evoked a discernable
evoked potential, which was always within A-ﬁber latency window
(<1 ms), at the proximal recording contact. Most of time (>90%), the
evoked response EMG was also observed. The physiological
threshold (PT), which evoked visible heart rate/respiratory change,
was usually 3 or 4  NT. Stimulus trains of 10-s durations were then
delivered, each with stimulation parameters randomly selected
from a range. In particular, pulsing frequency was 30 Hz, pulse
width was between 40 and 600 ms, stimulation intensity was between 0.5 and 10  NT. The stimulation conﬁguration was either
tripolar (cathode-center or cathode-corner) or bipolar (cathodecephalad or cathode-caudad). There were at minimum 15-s long
pauses between successive trains to ensure that physiological
measurements had fully recovered before a new train was delivered. The different stimulus trains were delivered once per animal,
in random order, to limit the total duration of each experiment to
3e4 h and prevent changes of the animal’s physiological state due
to prolonged anesthesia.
Another set of experiments was conducted to document the
physiological responses to different pulsing frequencies and pulse
counts. In these experiments, VNS consisted of 10-s long trains of

Methods
Animal preparation, anesthesia, physiological instrumentation
Thirty adult male Sprague Dawley rats (age 2e5 months and
weight between 300 and 550 gm) were used in the study under the
approval of the Institutional Animal Care and Use Committee at The
Feinstein Institutes for Medical Research. Rats were anaesthetized
using isoﬂurane (induction at 4% and maintenance at 1e2%) and
medical oxygen; anesthesia was maintained throughout the
experiment. Body temperature was measured with a rectal probe
and maintained between 36.5 and 37.5  C using a heating pad
(78914731, Patterson Scientiﬁc) connected to a warm water recirculator (TP-700 T, Stryker). ECG was recorded by using 3-lead
needle electrodes subcutaneously on the limbs and ampliﬁed using a commercial octal bio-ampliﬁer (FE238, ADI). Breathing was
monitored by using a temperature probe placed outside of the
1618
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Fig. 1. Electrodes, sensors and physiological signals involved in the experiments. (A) Schematic of an anesthetized animal with the typical locations of vagus nerve cuff
electrodes (stimulation: rostral, recording: caudal) and physiological sensors (green: nasal sensor; red: ECG sensors). (B) Representative effects of cervical VNS (top to bottom):
cessation of breathing (apnea) in the nasal sensor, drop in heart rate in the ECG and evoked nerve potentials in the electroneurogram (ENG), in response to a 10 s-long VNS train
(30 Hz, 300 ms pulses). (C) Individual sweeps of evoked nerve potentials aligned with the onset of stimulus pulse (grey traces), and stimulus-triggered average compound nerve
action potentials (black trace), extracted from the ENG in panel B. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this
article.)

100-ms or 600-ms long pulses, with pulsing frequency between 5
and 300 Hz, and stimulation intensity between 0.5 and 3  PT. In a
subset of these experiments, the same frequencies were tested with
shorter trains (2e10 pulses, 0.0067- to 5-s train duration,
depending on frequency) and intensities between 1 and 10  PT.

between the proximal and distal recording contacts, spaced apart
by a distance of 895 mm, of 1e2 ms, whereas EMG or line noiserelated signals should occur simultaneously on both recording
contacts [27] (Fig. 2A, panel III).
We conducted additional experiments to ensure that what we
considered nerve ﬁber activity was not EMG. Vecuronium, a
neuromuscular junction blocking agent, was infused intravenously
with a bolus dose (0.15 mg/kg) and continuous IV (0.15 mg/kg/min)
while the animal was ventilated with 41 breaths per minute and
4 ml tidal volume (SAR-1000, CWE Inc., Ardmore, PA). During
vecuronium infusion, the EMG component in the eCAP was
considerably suppressed while the neural components were still
visible (Figs. S2 and S9, Supplementary Materials). The resulting
time window for the majority of the EMG component was 2e6 ms,
consistent with other studies documenting VNS-induced laryngeal
motor-evoked potential in rats [27e29] (Fig. 2B). We computed Aand B-type ﬁbers amplitudes as the peak prominence and C-type
ﬁber amplitude was deﬁned as the peak-to-trough amplitude of
late (>6 ms) eCAP components. The C-ﬁber component of the eCAP
was clearly distinguishable from the EMG-related component at a
range of stimulus intensities, as shown by measurements made
with and without neuromuscular blocker (Figs. S9A and B, Supplementary Materials). The amplitude of the C-ﬁber component
increased with stimulus intensity, and saturated at intensities of
about 8e10 times threshold (Fig. S9C, Supplementary Materials).

Identiﬁcation and analysis of neural and EMG signals
Raw nerve signal traces from both recording contacts were
ﬁltered using a 1 Hz high-pass ﬁlter to remove the DC component.
Stimulus-evoked compound nerve action potentials (eCAPs) elicited from all pulses in each stimulus train were extracted by
average individual sweeps of nerve recording traces around the
onset of pulses (Fig. 1C). A custom-made buffer ampliﬁer was used
to record the induced voltage on the electrode during stimulation.
Stimulation artifact was suppressed ofﬂine by a recently proposed
method which subtracts the trace of the stimulation electrode
voltage from the eCAP with proper template matching and an edge
effect removal algorithm [28] (Fig. S1, Supplementary Materials).
Given the rough estimation of distance between the recording
and stimulation electrodes (5e6 mm), we ﬁne tune the distance in
analysis so that the latency windows can align well with the A-, Band C-ﬁber prominent peaks with pre-deﬁned conduction velocity
ranges for each ﬁber type (A: 5e120 m/s; B: 2e8 m/s; C: 0.1e0.8 m/
s) [21]. Fig. 2A shows representative eCAPs at 3 different intensities:
1  , 4  and 10  NT, including activity of different ﬁber types and
EMG. Signals from both contacts in the recording electrode, proximal and distal to the stimulating electrode, were collected (solid
and dashed black traces in Fig. 2A). This allowed us to distinguish
between neural and EMG signal components. For the given electrode spacing A- and B-ﬁbers had short latencies (<3 ms), while
slower C-ﬁbers occurred at longer latencies (>6 ms) [28]. To
discriminate C-ﬁber components from stimulus-evoked EMG, we
reasoned that C-ﬁber volleys should show a latency difference

Analysis of physiological signals
We computed the magnitude of EMG response from respective
eCAPs as the peak-to-trough amplitude of the (typically biphasic)
response within the EMG window; that amplitude was then
normalized by the mean EMG amplitude in that subject, recorded
at a speciﬁc set of VNS parameters (based on results shown in
Fig. S3, Supplementary Materials): intensity 6e8  NT, pulse width
1619
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Fig. 2. Quantiﬁcation of nerve ﬁber activation by and physiological responses to VNS. Three VNS trains (300 pulses, 300 ms pulse width, at 30 Hz) were delivered at 3 stimulus
intensities (1, 4 and 10 times the neural threshold, NT, from top to bottom), and stimulus-evoked compound action potentials (eCAPs), heart rate and breathing responses were
registered. (A) Average eCAP responses to single VNS pulses, after stimulus artifact suppression, for each of the 3 VNS intensities. Two eCAP traces are shown, one from each of the
recording contacts (black trace for proximal lead to the stimulating electrode, red line for the distal lead). Fiber-speciﬁc responses were measured as peak-to-trough amplitude of
eCAP components occurring within speciﬁc latency windows: A-ﬁber (0.3 mse1 ms, red shaded area), B-ﬁber (0.9 mse2.2 ms, green area) and C-ﬁber (5.5 mse16.7 ms, yellow
area); also shown is the window corresponding to stimulus-evoked EMG activity (2.5 mse10 ms, blue area), partially overlapping with the C-ﬁber window. Shown at the 10  NT
(bottom) panel are the amplitudes of A-, B- and C-ﬁber activation (shown in red, green and orange vertical arrows, respectively, along with their values). The relative latency shift in
the C-ﬁber response recorded by the 2 electrode leads (horizontal bar in bottom panel, 1.1 ms), indicates a slow-conducting neural source for this component. (B) Magnitude of
stimulus-evoked EMG for the 3 VNS intensities (vertical black arrow) measured as peak-to-trough amplitude of the EMG component of the corresponding eCAPs shown in panel (A).
The 2 eCAP traces (black and red) show no relative latency shift, indicating a non-neural source. (C) ECG and heart rate (HR, calculated with each cardiac cycle) traces before, during
(grey area) and after delivery of the 3 VNS trains. The HR response (DHR) is calculated as the difference between the mean HR before and during VNS, normalized by HR before VNS,
and its value is shown in each case. (D) Air ﬂow and breathing interval (BI, calculated with each breathing event) before, during and after VNS. The BI response (DBI) is calculated as
the difference between the mean BI before and during VNS, and its value is shown in each case. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the Web version of this article.)

mean HR “during stimulus”. The measured signals and corresponding derived variables (ECG and DHR, and nasal sensor temperature and DBI) are shown in Fig. 2C and D.

600 ms. Using a custom algorithm, ECG peaks corresponding to the
R waves were identiﬁed, and heart rate (HR) was computed from RR intervals. We deﬁned stimulus-induced change in HR (DHR) as
the difference between the mean HR during a 10-s epoch before the
onset of the stimulus train (“pre-stimulus”) and the mean HR
during the stimulus train (“during-stimulus”), divided the mean
pre-stimulus HR. In recordings from the nasal temperature sensor,
we identiﬁed peaks (end of expiration) and troughs (end of inspiration). We deﬁned the interval between two successive peaks (or
two successive troughs) as breathing interval (BI). We deﬁned the
stimulus-elicited change in breathing interval (DBI) as the difference between the mean pre-stimulus and the mean duringstimulus BI. In those experiments in which VNS trains were of
short duration, during which less than 2 R-R intervals occurred, we
used 5 R-R intervals immediately following the train to estimate

Regression and prediction models
A bivariate model was used to capture the relationship between
A-, B- and C-ﬁber amplitude and the related physiological variable
(EMG, DHR and DBI, respectively). Individual models were ﬁtted
from data for each subject (Fig. 4 A, B and C). After normalizing ﬁber
amplitudes and physiological responses to their maximum values
for a given subject, normalized data were used to generate a single
bivariate model for each ﬁber type across all subjects (Fig. 4 D, E and
F).
1620
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Results

A multivariate quadratic model was compiled for quantitative
estimation of relative amplitude of ﬁber activation (percent of
maximum for that subject), using four inputs from all the subjects:
EMG, DHR, DBI, and charge per pulse (Q), deﬁned as the product
between pulse width and the current intensity in units of NT. The
general form of the model was:

Neural and physiological responses to VNS
We wished to infer the magnitudes of A-, B- and C-ﬁber activation by using physiological responses to VNS that can be
measured rapidly and noninvasively in human subjects and
experimental animals. We delivered cervical VNS with different
stimulation parameters known to engage different ﬁber types.
Through a second recording electrode, also placed on the cervical
vagus, we registered stimulus-evoked compound nerve action potentials (eCAPs) and A-, B- and C-ﬁber responses, as well as
laryngeal EMG responses, were extracted. At the same time, we
monitored ECG and nasal air ﬂow and calculated the magnitude of
VNS-elicited changes, from a pre-stimulation baseline level, in
heart rate (DHR) and in breathing interval (DBI). Intensity threshold
values for neural (typically A-ﬁber) activity ranged between 12 and
30 mA (mean ± SD: 22.5 ± 6 mA) for 100 ms-long monophasic pulses.
To characterize the relationship between vagal ﬁber activation
and physiological responses, we ﬁrst documented how they both
changed in response to VNS of different stimulus intensities, pulse
widths and pulsing frequencies. Across all subjects, the mean (±SD)
amplitude of A-, B- and C-ﬁber responses were 59.01 ± 42.60 mV,
21.11 ± 15.33 mV, and 74.80 ± 73.70 mV, respectively. The mean
(±SD) latencies of ﬁber activity peaks were 0.4192 ± 0.0126 ms for
A-ﬁbers, 1.2315 ± 0.1777 ms for B-ﬁbers, and 9.7688 ± 1.4885 ms for
C-ﬁbers (Fig. S7, Supplementary Materials). The mean (±SD)
magnitude of evoked EMG, DHR and DBI responses were
57.03 ± 74.03 mV, 9.64 ± 12.27%, 2.64 ± 4.59 s, respectively: the
typical physiological responses to VNS were therefore muscle
contraction, slowing of the HR and prolongation of the BI. The
physiological responses elicited by VNS were statistically different
from the corresponding physiological measurements during the 10
s-long pre-stimulation baseline, for all threshold and suprathreshold intensities (upper-tail one-sided statistical t-test,
p < 0.001 for all 3 comparisons: EMGVNS vs. EMGbase, HRVNS vs.
HRbase and BIVNS vs. BIbase).
A-ﬁber amplitude and EMG magnitude both increased with
increasing stimulus intensity (Fig. 3A, left and middle panels), with
a linear relationship between them that was preserved across
stimulus intensities (Fig. 3A, right panel). Similarly, B-ﬁber amplitude and DHR magnitude also increased with increasing stimulus
intensity (Fig. 3B, left and middle panels), but this time the ﬁber
amplitude-response magnitude relationship had an exponential
form (Fig. 3B, right panel). C-ﬁber amplitude and DBI magnitude
started building up at signiﬁcantly higher stimulus intensities
(Fig. 3C, left and middle panels) and an exponential relationship
between C-ﬁber activation and the slowing of breathing was typically seen (Fig. 3C, right panel).

Fiber ampl:% ¼ a0 Q þ a1 EMG þ a2 DHR þ a3 DBI þ a4 Q 2
þ a5 EMG2 þ a6 HR2 þ a7 BI2
(1)
The model was trained and tested with leave-one subject-out
cross-validation. Brieﬂy, the entire dataset was divided in two
subsets: training set (data from all subjects except one), to build the
model, and the test set (the subject that was left out) to assess
model performance. The training procedure was repeated 100
times (100-fold random cross-validation method). To build the
model, we selected only those ﬁtted coefﬁcients showing statistical
signiﬁcance (F-test, p < 0.01) in at least 50 of 100 times. The last
model was developed by taking the medians of the selected coefﬁcients for each input term in Eq. (1). Finally, we computed performance by applying the model on data from the test set.
A 2-term asymptotic exponential model, akin to double exponential function, was computed to capture the relationship between each of the physiological responses (HR or BI) at a pulsing
frequency f with respect to the same response at 30 Hz (“frequency
gain”). The general form of the model was:





Frequency gain ¼ b0 þ b1 exp f=t þ b2 exp f=t
1

1

(2)

where b0 is a ﬁtting offset, b1 and b2 are the initial values, and t1
and t2 are the time constants of the exponential functions. The
coefﬁcients were optimized using Nelder-Mead simplex direct
search method with distinct initial value settings for two exponential terms.
Performance metrics and statistical analysis
To assess goodness-of-ﬁt performance of the different models,
the root mean square error (RMSE) and the normalized RMSE
values were computed.

sﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
PN
b 2
i ðyi  y i Þ
;
RMSE ¼
N

NRMSE ¼

RMSE
maxðyÞ  minðyÞ

where yi is the observed value for the i-th observation, b
y i is the
predicted value and N is the length of the observation.
After building the linear quadratic model for each ﬁber type, we
computed RMSE values. Chance performance level was set with a
permutation test [30]. We created surrogate data sets from the test
data by randomly shufﬂing the ﬁber-type label of each data point,
thereby destroying any relationship between inputs and outputs.
Then, we treated the surrogate dataset just like the original data
and computed the RMSE using the ﬁnal models. By repeating this
process 100 times, we created a distribution of “random performance” metrics; we considered model performance computed on
the original data signiﬁcant if it was smaller than the 5th percentile
of the random performance RMSE distribution.
The non-parametric Kruskal-Wallis test (KWT) was used to
compare different ﬁber activation evoked during VNS. A p value less
than 0.05 was considered statistically signiﬁcant. All the analyses
were performed using MATLAB 2017b software (MathWorks,
Natick, MA, USA).

Relationships between ﬁber amplitudes and physiological response
magnitudes
We then quantiﬁed the relationship between A-, B-, and C-ﬁber
amplitude and the magnitude of EMG, heart rate (DHR) and
breathing interval (DBI) responses, respectively. Based on our previous observations, we used a linear model to relate A-ﬁber amplitude to EMG magnitude. In all subjects, A-ﬁber amplitude and
magnitude of EMG response were positively and linearly correlated
(Fig. 4A). By normalizing the neural and the EMG responses by their
maximum values within each subject, we were able to ﬁt data from
all subjects with a single linear function (Fig. 4D). Normalized values
of A-ﬁber amplitude and EMG magnitude generally increased with
increasing charge per pulse (stimulus intensity  pulse width) of the
pulses within a given stimulus train (Fig. 4D). Using a similar
1621
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Fig. 3. Nerve ﬁber activation and physiological responses with increasing stimulus intensity. Data are from the same subject in which VNS was delivered in trains of 300 pulses,
100 ms pulse width, at 30 Hz. (A) Amplitude of A-ﬁbers (left panel) and magnitude of stimulus-evoked EMG (middle panel) plotted as a function of stimulus intensity (“capture
curves”), in units of neural threshold (NT). Plotting the same data as A-ﬁber vs. EMG pairs reveals a linear relationship (right panel). (B) Capture curves of B-ﬁbers (left) and heart
rate responses (DHR, middle), and exponential relationship between them (right). (C) Capture curves of C-ﬁbers (left) and breathing interval responses (DBI, middle), and exponential relationship between them (right). Note that C-ﬁber and DBI responses are captured at higher intensities.

procedure, we related B-ﬁber amplitude to DHR magnitude. In this
case, an exponential model was used to ﬁt the data for individual
subjects (Fig. 4B) and, after normalization, collectively for all subjects
(Fig. 4E). Again, normalized B-ﬁber amplitude and DHR generally
became greater as charge increased (Fig. 4E). We repeated these
steps for C-ﬁber amplitude and DBI magnitude and used an exponential model to ﬁt the data (Fig. 4C and F). In this analysis, data from
several stimulus trains were omitted since in C-ﬁbers were not always activated and/or there was not always a breathing response to
VNS. This resulted in a smaller dataset than those of A- and B- ﬁbers.
These bivariate correlations were similar in shape between bipolar
and tripolar stimulation electrode conﬁgurations (Fig. S10, Supplementary Materials).
To assess goodness of ﬁt, we computed the normalized root
mean square error (NRMSE) values for each single-subject ﬁt, for
each of the 3 ﬁber amplitude-physiological response magnitude
models. Median NRMSE was 0.173 (range: 0.085e0.266) for the Aﬁber vs. EMG model, 0.192 (0.119e0.232) for the B-ﬁber vs. DHR
model, and 0.098 (0.044e0.179) for the C-ﬁber vs. DBI model
(Fig. 4G).

breathing is affected in distinct ways by afferent A- and by C-ﬁbers
[31]. We further characterized the relationship between A- and Cﬁber amplitude, and DBI. We classiﬁed breathing responses to individual VNS trains in 3 groups: “bradypnea”, if DBI was >0.2 s and
2 or more breathing events occurred during the 10-s long stimulus
train, “apnea”, if 1 or no breathing events occurred during the
stimulus train, and “no change in breathing”, if DBI was <0.2 s
(Fig. 5A). For each VNS train, the amplitudes of A- and C-ﬁber activity were normalized to their maximum values in the corresponding subject. We found that A-ﬁbers were roughly equally
activated in apnea and bradypnea (p ¼ 0.83, KWT), while there was
signiﬁcantly greater A-ﬁber activation in bradypnea responses vs.
no change in breathing (p < 0.01, KWT). On the other hand, there
was signiﬁcantly greater C-ﬁber activation in apnea compared to
either bradypnea or no change in breathing (p < 0.001, KWT for
both comparisons) (Fig. 5B). These ﬁndings suggest that moderate
changes in the breathing pattern are typically associated with
activation of A-ﬁbers alone. However, apnea responses were
frequently associated with C-ﬁber activation. Since non-ﬁberselective stimulation waveforms were used in this study, C-ﬁber
activation could happen alone or, most likely, in combination with
A-ﬁber activation.

A- and C-ﬁber activation associated with breathing responses
Despite our ﬁnding of an association between C-ﬁber amplitude
and magnitude of the breathing response (DBI), it is known that
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Fig. 4. Relationships between nerve ﬁber activation and physiological responses. (A) Relationship between A-ﬁber amplitude and magnitude of stimulus-evoked EMG, in each of
10 subjects. Each dot represents an A-ﬁber vs. EMG measurement pair from a single VNS train. Colors represents different animals, and each curve represents the best linear ﬁt for
the data from that animal. (B) Relationship between B-ﬁber amplitude and magnitude of the heart rate response (DHR). Individual curves represent single exponential ﬁts. (C)
Relationship between C-ﬁber amplitude and magnitude of the breathing interval response (DBI). (D) Same data as in panel (A), but after each data pair was normalized to the
maximum values registered in the corresponding animal. Color represents relative charge per phase (stimulus intensity in units of neural threshold (NT)  pulse width in ms),
ranging from 0.5  NT at 100 ms(blue) to 10  NT at 600 ms(yellow). Curve represents a linear ﬁt model. (E) Similar as (D), but for normalized values of B-ﬁber activation and DHR
response. Curve represents a single exponential ﬁt model. (F) Similar as (D), but for normalized values of C-ﬁber activation and DBI response. Curve represents a single exponential
ﬁt model. (G) Normalized root mean square errors (NRMSE) for each of the individual ﬁts shown in panels (A) (A-ﬁber amp. vs. EMG), (B) (B-ﬁber amp. vs. DHR) and (C) (C-ﬁber
amp. vs. DBI). Single dots represent the NRMSE associated to each subject for the three models. Barplots report the median and the interquartile range of all NRMSE values within
each model. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
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Fig. 5. A- and C-ﬁber activation associated with breathing responses. (A) Example average eCAP traces from the two recording electrode contacts (solid black from proximal,
dashed grey from distal lead) and corresponding breathing response, in a case of bradypnea (left panels) and apnea (right panels). (B) Scatter plot of pairs of A-ﬁber vs. C-ﬁber
amplitudes recorded in 10 subjects, color-coded by breathing response group: apnea (red dots), bradypnea (green dots) and no effect in breathing (blue dots). Fiber amplitudes are
normalized to the maximum value registered in each subject. Stars represent the center the 2-D distributions for each of the 3 breathing response groups, and boxplots represent
the median and interquartile range of A- and C-type ﬁber amplitudes for each of the 3 groups (*: p < 0.01 Kruskal Wallis test). (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the Web version of this article.)

Models to estimate vagal ﬁber activation

frequencies, we performed experiments to quantify how physiological responses change with frequency, from 5 to 300 Hz. The
DHR response increases with increasing frequency, reaches
maximum at 50e100 Hz and then it declines (Fig. 7A). In contrast,
the DBI response shows an abrupt increase that saturates around
50e100 Hz (Fig. 7B). Stimulus-evoked EMG activity did not change
with pulsing frequency, as its time-course is shorter than typical
inter-stimulus-intervals (Fig. S5, Supplementary Materials), and
was not subjected to this analysis. We used 2-term exponential
functions (Eq. (2)) to create a “frequency gain” model that translates
the physiological response (DHR or DBI) observed at a given frequency to that observed at 30 Hz (Fig. 7C, and Table 2 with better
precision). This translation allows the estimation of vagal ﬁber
amplitudes, using the previously established ﬁber activation
models, for any pulsing frequency. Individual data points used in
compiling these models are shown in Fig. S4 (Supplementary Materials). Even though the physiological responses scale with stimulus intensity, their dependence on pulsing frequency is stable.
When short-duration stimulus trains were delivered, DHR response
had a similar dependence on frequency (Fig. S6A, Supplementary
Materials), and generally increased with pulse count (Fig. S6B,
Supplementary Materials). However, no signiﬁcant DBI responses
were documented for trains shorter than 5e10 s (data not shown).

We then attempted to estimate quantitatively the percentage of
the A-, B- and C-ﬁber activity evoked by VNS, by considering the
magnitude of the observed physiological responses and some
stimulation parameters. For that purpose, we built multivariate
quadratic models (Eq. (1)) using four independent variables:
Normalized EMG amplitude, DHR, DBI, and stimulus charge per
pulse (normalized intensity  pulse width). Among all physiological readouts, EMG require normalization within subject because
the magnitude range varies signiﬁcantly across different animals,
and the reference was consistently selected from the stimulation
parameter, 6e8  NT, 600 ms, which generally has maximum EMG
response (Fig. S3, Supplementary Materials). Table 1 shows the
signiﬁcant coefﬁcients for each model. After models were
computed, chance performance levels were determined by means
of surrogate distributions and were used to determine signiﬁcance
of model performance.
Regarding model performance, RMSE for A-, B- and C-ﬁber
models were signiﬁcantly better than chance, for both training and
test data sets (Fig. 6A, B, C). Individual estimated and measured
ﬁber activation percentage from all animals as test data sets are
shown in Fig. 6D, E, F; data points in A- and C-ﬁber models (Fig. 6D
and F) are generally closer to unity line, and therefore more accurate, compared to the B-ﬁber model (Fig. 6E). Additionally, Table S1
reports the amount of variance explained (R2 value) for the 3 ﬁber
models in each subject. Finally, to understand the effect of each
single predictor, we reported in Table S2 the Proportional Reduction
of Error (PRE) as suggested in Ref. [32]. Brieﬂy, we computed the
error as the residual sum of squares (RSS) obtained with the model
A (augmented, using all the predictors) and the model C (compacted, without one predictor) to see the effect of each parameter
using the following formula: PRE ¼ 1 e RSSA/RSSC.

Discussion
In recent years, quantiﬁcation of the engagement of different
ﬁber types by VNS has been pursued systematically by recording
stimulus-evoked compound nerve action potentials (eCAPs)
directly from the nerve [15]. Even though several chronic VNS

Table 1
Signiﬁcant coefﬁcients of the linear and quadratic terms in each of the models for
estimating ﬁber activation, according to the general form of Eq. (1).

Scaling of physiological responses with pulsing frequency
Our ﬁber amplitude estimation models depend on physiological
responses elicited by VNS at 30 Hz, a pulsing frequency commonly
used in clinical VNS. In order to generalize these models to other
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86.94
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e
e
e

21.98
34.66
e

e
0.042
e

e
e
e

Y.-C. Chang, M. Cracchiolo, U. Ahmed et al.

Brain Stimulation 13 (2020) 1617e1630

Fig. 6. Performance of models to estimate A-, B and C-ﬁber activation. (A) RMSE of the A-ﬁber model for both train and test sets. Bars represent median RMSE and error bars the
interquartile range. The horizontal dashed line indicates chance level, as computed by a permutation test. (D) All actual (measured) A-ﬁber activation percentage and corresponding
estimated using the ﬁnal A-ﬁber model from Table 1. (B and E) Same as (A and D) but for B-ﬁber model. (C and F) Same as before, but for C-ﬁber model.

electrodes for recording might increase the risk for surgical complications, accentuate tissue response or affect the integrity of
nerve ﬁbers [36]. Given those limitations, a method to quantitatively estimate the level of ﬁber engagement by cervical VNS using

paradigms have been tested in various animal models of disease
[13,33e35], no stable nerve recordings with longevity and stability
have been demonstrated [23], and recording eCAPs from the human vagus is not currently feasible. Placement of extra nerve

Fig. 7. Scaling of physiological responses with pulsing frequency. (A) Dependence of the heart rate response (DHR) on pulsing frequency. Individual points and error bars
represent the average and standard error, respectively, of DHR responses to VNS trains of a given pulsing frequency with different amplitudes and pulse widths, across 5 animals.
Dash line represents the ﬁt line using a 2-term exponential model. (B) Same as in panel (A), but for the breathing interval response (DBI). (C) Graphical representation and
mathematical equation of the “frequency gain” model for DHR and DBI, with “unity gain” corresponding to the responses at 30 Hz.
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lower intensity levels than HR or breathing responses. This suggests
that one can get measurable EMG, and therefore somatic afferent
Аb ﬁber activation, at lower intensities than those producing heart
rate changes (B-ﬁbers) or breathing changes (Ad and C ﬁbers). This
has implications for the use of vagal evoked potentials, evoked
cortical activity or fMRI changes for measuring afferent vagal activation and optimizing VNS-based neuroplasticity paradigms [44],
as part of those cortical responses could reﬂect “myogenic” sources.
Finally, it is known that laryngeal EMG is evoked ﬁrst by activation
of ﬁbers of the recurrent laryngeal nerve, located inside the cuff,
and eventually by activation of the superior laryngeal branch
located outside the cuff through current leakage [45,46]. Even
though measures were taken to provide additional insulation to the
neural interface in our experiment, it is likely that the linearly
increasing evoked EMG results from co-activation of hypoglossal
nerve and pharyngeal branch ﬁbers by leaking current, especially at
high stimulation intensities.
We found that B-ﬁber activation by VNS is related to HR drop
(Fig. 4B, E), in agreement with ﬁndings in other animal studies
[37,38,47]. Indeed, the vagus innervates the sinoatrial and the
atrioventricular nodes, with negative chronotropic and dromotropic effects, respectively [48e50]. Studies in humans suggest that
bradycardia is elicited by increasing VNS intensity or pulse width,
both consistent with B-ﬁber activation [51]. The relationship between B-ﬁber activation and HR drop is not linear, but exponential
(Fig. 4B, E). This suggests that ﬁber types with higher activation
thresholds, like C-ﬁbers (Fig. 3B and C) may contribute to the
cardio-inhibitory effect of VNS beyond maximum activation of Bﬁbers. Bradycardia can indeed be induced by selective stimulation
of efferent C- ﬁbers [52,53], whereas activation of afferent ﬁbers,
probably A- and C-type, can decrease HR by centrally enhancing
parasympathetic efferent outﬂow and reducing sympathetic
efferent outﬂow [47]. Finally, optogenetic activation of vagal A- and
C-type afferent ﬁbers caused bradycardia [31]. In our study, quantifying the B-ﬁber response was challenging because its amplitude
was small and its latency was short, in some cases neighboring the
A-ﬁber response. For these reasons, we sometimes had to measure
the B-components in eCAPs manually and that could be partially
responsible for the somewhat lower estimation accuracy of the Bﬁber model (Fig. 6D, E, F).
We analyzed the effects of VNS on breathing and quantiﬁed
their relationship to A- and C-ﬁber activation. C-ﬁber amplitude
correlates strongly with breathing changes: weak C-ﬁber activation
was associated with slower breathing during VNS, whereas strong
C-ﬁber activation with apnea (Fig. 5A and B). C-ﬁbers were engaged
at relatively large charge injections (Fig. 4F), reﬂected in the coefﬁcient assigned to charge per phase in the C-ﬁber model (Table 1).
A-ﬁbers were sometimes associated with breathing changes, but
that relationship was not as consistent: the amplitude of A-ﬁber
activation during bradypnea was signiﬁcantly greater compared to
lack of breathing response (Fig. 5B). Our ﬁndings are consistent
with the known role of afferent A- and C-ﬁbers in the neural
regulation of breathing [54,55]. Stimulation of A-ﬁbers leads to a
decrease in breathing rate through inhibition of the central inspiratory drive [56], a response happening normally as part of the
Herring-Breuer reﬂex [57]. Our recording and stimulation conﬁguration minimized the afferent component of evoked A-ﬁber activity, hence the lack of consistent relationship between A-ﬁbers
and breathing changes. Similarly, stimulation of C-ﬁbers leads to
decrease of tidal volume, increase of respiratory rate, constriction of
airways, and defense reﬂex associated with coughing [58]. Fiber
engagement in VNS with rectangular waveforms, like those used in
our study, follows a size principle [59] (Fig. 3): small stimulation
intensities and/or short pulse widths activate A-ﬁbers and lead to
moderate prolongation of the BI (Fig. 5B), whereas higher

Table 2
Coefﬁcients of the nonlinear 2-term asymptotic exponential function for each of the
2 physiological responses (DHR and DBI), that allow calculation of the “frequency
gain” in Eq. (2).
Model

b0

b1

t1

b2

t2

DHR(f)
DBI(f)

0.8298
8.7648

37.1404
1.3683

62.9058
12.9306

36.1449
7.6528

67.8152
10,189

physiological parameters that, ideally, can be registered noninvasively, would be of use in preclinical and clinical research, and
eventually in the clinical practice of VNS. To the best of our
knowledge, ours is the ﬁrst study to establish such a quantitative
estimation method, even though attempts have been made to
relate B-ﬁber activity to changes in heart rate [37] and to qualitatively calibrate functional thresholds for vagal ﬁber engagement
[38].
First, we examined the feasibility of predicting the level of
activation of different ﬁber types using physiological variables with
a univariate (linear and nonlinear) regression model. The selection
of physiological responses to be correlated with activation of each
ﬁber type was based on established physiological functions of the
vagus and on our own past studies [28]. We then compiled a datadriven model for each ﬁber type that estimated the amplitude of its
activation by using corresponding physiological responses, and in
the case of C-type ﬁbers, the amount of injected charge. Performance of each of the models was evaluated with data not used in
the building of that model, quantiﬁed and compared to the chance
performance level. The three models are simple, intuitive and in
line with what we expected: A-ﬁbers are related to only the
observed EMG amplitude, B-ﬁbers to both the heart rate (HR)
response and EMG amplitude, and C-ﬁbers to both the prolongation
of the breathing interval (BI) and to the injected charge per phase.
VNS evoked ﬁber activity and physiological responses
The linear relationship between VNS-elicited EMG activity and
evoked A-ﬁber amplitude (Fig. 4A, D) agrees with what is known
about the vagal innervation of laryngeal muscles and the effects of
VNS on their contraction. Efferent A-ﬁbers in the superior and
recurrent laryngeal nerves, both being branches of the cervical
vagus, innervate intrinsic muscles of the larynx and account for a
majority of large myelinated ﬁbers in the trunk of the cervical vagus
[39]. Electrophysiological studies have shown that activation of Aﬁbers by VNS leads to contraction of laryngeal muscles, and; in
patients with cervical vagus implants, high stimulation intensities
produce laryngospasm [40,41]. By comparing eCAPs with and
without a neuromuscular blocker (Fig. S2, Supplementary Materials), we established that VNS-elicited EMG occurs 3e10 ms poststimulus, consistent with monosynaptic activation of innervated
muscles. It is worth noting that A-ﬁber amplitude in these experiments reﬂects activation of both efferent and afferent A-ﬁbers,
which convey sensory information from the lungs. In our experiments, the recording electrode was placed caudally to the stimulating electrode and the stimuli were delivered in the cathodecaudad polarity, promoting the activation of efferent ﬁbers [43].
Using this conﬁguration, it is likely that a signiﬁcant part of the Aﬁber component corresponds to activation of efferent A-ﬁbers, as
some of the afferent A-ﬁber activity is blocked by the hyperpolarizing anode [43]. This would explain the relatively strong
linear relationship between A-ﬁber amplitude and EMG activity,
and the weaker relationship with changes in breathing (Fig. 5). The
use of normalized EMG values in the model minimizes variability
introduced by the method for recording or analyzing EMG activity.
Interestingly, EMG responses were documented at signiﬁcantly
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different in awake subjects, or in subjects anesthetized with
different agents. It is also likely that the use of isoﬂurane in our
study is partly responsible for the relative absence of tachycardia
responses to VNS, seen in other papers not using isoﬂurane [69]. For
that reason, the B-ﬁber-bradycardia association may be less
obvious in situations where the vagal circuits involved in these
responses are less affected by anesthesia, or it may be more
dependent on stimulation parameters. For example, smaller intensities may produce tachycardia, due to activation of sympathetic
vagal ﬁber or vagal-sympathetic reﬂexes [69], whereas higher intensities may still produce bradycardia. Given the noninvasive nature of the physiological measurements used in the models we
propose, future experiments in awake, behaving animals using a
wide range of stimulation parameters will be needed to address
this source of variability.
Our analysis is based on the assumption that ﬁber engagement
and eCAP amplitude are linearly related. However, studies have
shown that the distribution of nerve ﬁbers is non-uniform within
the cervical vagus nerve, even in the relatively simple rodent nerves
[70,71]. Fibers that lie closer to the stimulating or recording electrode are easier to be excited or contribute more heavily to the eCAP
measurements; both effects are more prominent with larger ﬁbers.
As the electrode in our study only directly interface a part of the
nerve trunk, there is a chance that some ﬁbers contribute more
than others to the eCAP signature or to the physiological response,
in a manner inversely proportional the location to those ﬁbers
relative to the recording or stimulating electrode. This might
inevitably lead to errors while quantifying the relationship between eCAP-resolved ﬁber engagement and physiological effects.
These relationships were similar between bipolar and tripolar
stimulating electrode conﬁgurations (Fig. S10, Supplementary
Materials), so the electrode geometry itself did not appear to
introduce a signiﬁcant confounding factor to these models. It is
noteworthy that, even though the absolute error of the proposed
models was 20e30 (for an output 0e100), the relative error depends on the level of ﬁber recruitment: for a recruitment level of
about 20%, the median relative error would be 42% for A-ﬁbers, 50%
for B-ﬁber and 40% for C-ﬁbers.
Several limitations arise from the choice of the rat as our animal
model, which posed constrains on the distance between the stimulating and recording sites (typically 5e6 mm). As the distance was
measured with a mm accuracy, which introduces uncertainty
around the exact latency windows, in each experiment, the latency
window corresponding to each ﬁber type was deﬁned on the basis
of the conduction velocity range for that ﬁber type [72], while
taking into account the actual, measured latency of the preeminent peak of the respective eCAP component. This accounted
essentially to a slight “ﬁne-tuning” of the latency window for a ﬁber
type to encompass a clear eCAP component corresponding to that
ﬁber type, when such a component was present. This short distance
also limits our ability to resolve activation of the several A-ﬁber
subtypes, each with different physiological functions and conduction velocities [72]. At this distance, the faster A-ﬁbers, Aa (motor
efferent) and Аb (somatic sensory from laryngeal muscles and ear),
would have latencies around 100 ms. With stimulus pulse widths
over 100 ms and a sampling period of 33 ms, detecting these components was not feasible. The A-ﬁber amplitude we measure likely
encompasses slower A-subtypes, Ag (motor efferents) and Аd
(aortic baroreceptor afferents and lung stretch receptors), with
expected latencies of 100e1000 ms. The latencies of the A-ﬁber
peaks in our measurements were within that range (Fig. S7, Supplementary Materials). Amplitude measurements of slower Asubtypes and of B-ﬁbers may also confound each other, as those
ﬁber types have overlapping conduction velocities; moreover,
activation of those ﬁber types has similar effects on heart rate [73].

intensities and/or longer pulse widths are more likely to engage
both A- and C-ﬁbers, resulting in a combined inhibitory effect on
breathing and either greater prolongation of the BI or apnea
(Fig. 5B).
VNS conﬁguration and parameter selection
In our study, we used monophasic pulses, as they result in
shorter and simpler artifact shapes and yield better artifact suppression for eCAPs. The monophasic design can also prevent the
confounding of the second phase acting as “cathodic” on the return
electrode which might initiate action potentials from a different
point. Monophasic pulses are associated with modestly lower
thresholds for all ﬁber types [60]. They are also not common in
clinical applications, for the purpose of charge-balancing and
chronic neural interface safety. For these reasons, and given the
clinical necessity for biphasic pulses, it is likely that the relationship
between nerve ﬁber activation and non-invasive physiological
measures in humans will be more complex.
In terms of stimulation waveform, we used square pulses, of
different intensities and pulse widths, that generally do no selectively engage ﬁber types; instead, ﬁber recruitment follows a size
principle: ﬁber with the largest diameter (A-type) and recruited
ﬁrst and those with the smallest diameter (C-type) are recruited
last. Several stimulation strategies, such as temporal patterning
[24], asymmetrical waveforms [61], have been used to reverse this
order. Furthermore, in large animals, multi-contact electrode have
been shown to elicit different physiological responses depending
on which fascicle was targeted [62]. Some of studies also show good
correlations between different ﬁber components and physiological
responses [24], implying that our model may not be relevant only to
square pulses and the “default” recruitment order, but may be
generalizable to different stimulation parameters. In that sense, it
will be interesting to test the validity of our models under conditions of ﬁber type- or fascicle-selective VNS.
The VNS trains used in the modeling part of our study had a
ﬁxed pulsing frequency of 30 Hz. Even though 30 Hz is common in
preclinical and clinical studies, it is known that pulsing frequency
has a signiﬁcant effect on physiological responses, both afferent
[63] and efferent [64]. At the same time, it does not affect nerve
responses to single pulses, due to lack of temporal summation
(Fig. S5, Supplementary Materials). That means that the ﬁber
models, as they were (Table 1), would not translate to other frequencies. In order to make the models generalizable to other frequencies, we computed formulas that re-scale the relevant
physiological responses to those observed at 30 Hz (Fig. 7 and
Table 2). These formulas rely on responses observed during 10 slong trains (or during the ﬁrst 10 s of longer VNS trains). Even
though train durations <10 s are uncommon in experimental or
clinical VNS studies, we found that shorter trains had similar effects
on the HR response (Fig. S6, Supplementary Materials) but not on
the BI response, which required train durations of at least 5e10 s
(data not shown).
Limitations
Our study has several limitations. First, the experiments were
performed under isoﬂurane anesthesia. It is unlikely that anesthesia affects eCAPs, as those depend on the excitability of axons
close to the stimulating electrode. However, it almost certainly affects the physiological responses to VNS: isoﬂurane suppresses
motor vagal activity to the heart [65] and lungs [66], it suppresses
afferent and efferent arms of the baroreﬂex [67] and is a potent
depressant of respiratory function [68]. Therefore, it is likely that
the coefﬁcients of the models compiled in this study will be
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Code availability

Despite the use of a slightly slower-than-standard latency window
for B-ﬁbers and a peak-to-trough (rather than trough-to-peak)
method for measuring B-ﬁber amplitude (Fig. 2), which typically
shifted that measurement to a latency beyond the A-ﬁber range, it
is likely that our cardioinhibitory “B-ﬁber” model reﬂects to an
extent activation of Ad ﬁbers and the effects of their activation.
Some of the issues with “blurring” amplitude estimates between
different ﬁber types could be addressed in a large animal, rather
than a rodent, model in which the distance between the stimulating and recording site can be signiﬁcantly longer [15]. It is likely
that the resolution of eCAP components at a more “expanded”
temporal scale in the large animal model will result in different,
and more accurate, model coefﬁcients. In addition, the relatively
“simple” anatomy of the vagus in rodents, with one or two fascicles,
is different than the multi-fascicular anatomy found in large animals and in humans [70]. This fascicular organization of the human
cervical vagus will likely affect the coefﬁcients of the models, as
different fascicles seem to contain populations of different ﬁber
sub-types [70]. Finally, given the lack of a clinical, fully implantable
recording vagus electrode, collecting detailed eCAP and physiological measurements in humans outside of the operating room is
currently not feasible; intra-operative experimental sessions are a
possibility but those would be limited in time and will likely not
generate enough data to train models that generalize well. For all
those reasons, documenting eCAPs and physiological effects of VNS
in a representative large animal model, like the swine [70], will be
essential to understanding the clinical application potential of our
approach.

The code used for the data analysis and modeling are can be
cloned from https://github.com/ychang3/VNS-Fiber-Engagement.
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prospective clinical studies as predictors of other, more long-term
physiological and clinical effects of VNS.
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